Ascend Capital’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Ascend Capital’s Portfolio CELGZ Stock Details CELGZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-34,306	Closed	-$35K	–	195
2016 Q3	$35K	Sell	34,306 -16,408	-32%	-$19.8K	﹤0.01%	118
2016 Q2	$74K	Buy	+50,714	New	+$65.3K	﹤0.01%	138

Other funds holding CELGZ

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return

UAS

United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MSTVIM

Messner & Smith Theme Value Investment Management San Diego, California $60.3M AUM 16.8% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Ascend Capital's CELGZ Position: Q4 2016 in Review

Ascend Capital sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2016, closing a stake of 34,306 shares — an estimated $35K sold.

Ascend Capital first reported a position in CELGZ in Q2 2016 and held it in 2 quarters. The position peaked at $74K in Q2 2016. 26 funds tracked by Wall St. Rank hold CELGZ as of Q4 2016.

Ascend Capital reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2016 after selling out during the quarter.
Ascend Capital sold 34,306 Celgene Corporation Contingent Value Rights shares in Q4 2016, an estimated $35K.
Ascend Capital first reported a position in Celgene Corporation Contingent Value Rights in Q2 2016 and held it in 2 quarters.
Ascend Capital's Celgene Corporation Contingent Value Rights position peaked at $74K in Q2 2016.
26 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2016.

Based on Ascend Capital's 13F filing for Q4 2016, filed 13 Feb 2017.